Abstract
Although some existing evidence supports the addition of chemotherapy (CT) to radiation therapy (RT) for anaplastic oligodendroglioma treatment, controversy about both the criteria for suitable candidates and the optimal treatment schedule remains. We reviewed data from 376 newly diagnosed anaplastic oliogodendroglial tumor patients from nine Korean institutes were reviewed from 2000 to 2010. Total tumor removal was performed in 146 patients. More than 85 % of the entire patients received postoperative RT, and 59 % received CT. Approximately 50 % (n = 189) received CT in addition to RT and 9 % (n = 32) received CT only. A multivariate analysis revealed that younger age, frontal lobe location of the tumor, gross total removal, 1p/19q codeletion, and initial RT were associated with longer progression-free and overall survival rates. No difference was observed in outcomes from the treatment that included either temozolomide or PCV (procarbazine, lomustine, and vincristine) in addition to RT regardless of the 1p/19q deletion status. A clear improvement in progression-free and overall survival was observed for RT and combined CT/RT in compared with CT only. Postoperative RT appears to improve survival for entire group thus total removal and 1p/19q codeletion may not be sufficient criteria to omit RT as a treatment option. These results suggest that RT should continue to be offered as the standard treatment option for patients with anaplastic oligodendroglial tumors.
Similar content being viewed by others
References
van den Bent MJ, Kros JM, Heimans JJ et al (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 51:1140–1145
Paleologos NA, Macdonald DR, Vick NA, Cairncross JG (1999) Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology 53:1141–1143
Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645
Brandes AA, Tosoni A, Vastola F et al (2004) Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101:2079–2085
Cairncross G, Wang M, Shaw E et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
van den Bent MJ, Brandes AA, Taphoorn MJ et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350
Panageas KS, Iwamoto FM, Cloughesy TF et al (2012) Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-oncology 14:761–767
Yu T, Kang HC, Lim DH et al (2015) Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. J Neuro-oncology 121:531–539
Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Abrey LE, Louis DN, Paleologos N et al (2007) Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro-oncology 9:314–318
Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710
Magrini SM, Ricardi U, Santoni R et al (2006) Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys 65:788–799
Lassman AB, Iwamoto FM, Cloughesy TF et al (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 13:649–659
Gorlia T, Delattre JY, Brandes AA et al (2013) New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49:3477–3485
Brandes AA, Nicolardi L, Tosoni A et al (2006) Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro-oncology 8:253–260
McGirt MJ, Chaichana KL, Gathinji M et al (2009) Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110:156–162
Ducray F, del Rio MS, Carpentier C et al (2011) Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. J Neuro-oncol 101:457–462
Gan HK, Rosenthal MA, Dowling A et al (2010) A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. Neuro-oncology 12:500–507
Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880
Mikkelsen T, Doyle T, Anderson J et al (2009) Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. J Neurooncol 92:57–63
van den Bent MJ, Taphoorn MJ, Brandes AA et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525–2528
van den Bent MJ, Chinot O, Boogerd W et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599–602
Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: a clinical efficacy trial. J Neurooncol 79:153–157
Han K, Ren M, Wick W et al (2014) Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-oncology. 16:696–706
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 352:987–996
Erdem-Eraslan L, Gravendeel LA, de Rooi J et al (2013) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 31:328–336
Minniti G, Arcella A, Scaringi C et al (2014) Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers. J Neurooncol 116:275–282
Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381–1393
Burger PC (2002) What is an oligodendroglioma? Brain Pathol 12:257–259
Wiestler B, Capper D, Holland-Letz T et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451
Reuss DE, Sahm F, Schrimpf D et al (2015) ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 129:133–146
Frenel JS, Leux C, Loussouarn D et al (2013) Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol 114:85–91
Zou P, Xu H, Chen P et al (2013) IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 8:e68782
Acknowledgments
This work is the collaborative effort of The Brain Tumor Committee of the Korean Radiation Oncology Group.
Funding
Korean Radiation Oncology Group and Cancer Control Program from the Korean Ministry of Health & Welfare (#0820010 to Kim IA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kang, HC., Yu, T., Lim, D.H. et al. A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13–12. J Neurooncol 125, 207–215 (2015). https://doi.org/10.1007/s11060-015-1902-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-015-1902-2